The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.
Completed
- Conditions
- Essential Hypertension
- Registration Number
- NCT01295021
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.
- Detailed Description
MC MD
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1514
Inclusion Criteria
- Newly diagnosed essential hypertension patients will be eligible for the study.
- Average of two or more systolic BP readings ≥ 140mmHg or diastolic BP readings ≥ 90mmHg
Exclusion Criteria
- History of coronary artery disease
- History of diabetes
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of SO in newly diagnosed hypertensive patients Visit 1-3: heart rate & Blood pressure, treatment presribed by physician. The interval between visit 1 and visit 2 is upto 4 weeks and interval between visit 2 & visit 3 is upto 4 weeks depending on Investigators discretion.
- Secondary Outcome Measures
Name Time Method Subjective symptoms noticed by the doctor. 1st visit Association of SO and heart rate. Visits 1-3 To record the drugs used in the treatment of patients diagnosed with hypertension. Visits 1-3
Trial Locations
- Locations (1)
Research Site
🇮🇳Warangal, India